Moleculin Biotech (NASDAQ:MBRX) announced its earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05), Fidelity Earnings reports.
Shares of MBRX traded down $0.03 during mid-day trading on Wednesday, hitting $1.18. The company’s stock had a trading volume of 12,310 shares, compared to its average volume of 10,739,746. The stock has a market capitalization of $42.29 million, a P/E ratio of -2.37 and a beta of 2.26. Moleculin Biotech has a 1-year low of $0.78 and a 1-year high of $3.15.
MBRX has been the subject of a number of recent research reports. ValuEngine cut Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Maxim Group reaffirmed a “buy” rating and set a $3.00 price objective on shares of Moleculin Biotech in a research report on Tuesday, February 5th. Finally, Zacks Investment Research cut Moleculin Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 14th.
WARNING: This article was originally reported by Zolmax and is owned by of Zolmax. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://zolmax.com/investing/moleculin-biotech-mbrx-posts-earnings-results-misses-expectations-by-0-05-eps/3084843.html.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Featured Article: Risk Tolerance
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.